VDRFF (VDRFF)

On July 31, 2026, Vertex Pharmaceuticals Inc (NASDAQ: VRTX) prepares to report its Q2 earnings after market close on August 3. Investors and analysts alike are

The analyst fair value estimate for V.F. has shifted slightly, now sitting at about US$19.45 compared with roughly US$20.19 previously. This adjustment comes as recent Street commentary shows a split view on V.F., with some analysts encouraged by brand momentum and others emphasizing execution ...

Moby summary of V.F. Corporation's Q1 2027 earnings call

VFC's Q1 loss widens as revenues fall 5.2%, but margin gains, lower net debt and a raised fiscal 2027 sales outlook signal improving trends.

The headline numbers for V.F. (VFC) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.